Dynamics of Hepatitis B Virus Pregenomic RNA in Chronic Hepatitis B Patients With Antiviral Therapy Over 9 Years

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2022 May 16

PMID 35572978

Authors

Jiali Pan

Yu Tian

Jinghang Xu

Hao Luo

Ning Tan

Yifan Han

Qian Kang

Hongyu Chen

Yuqing Yang

Xiaoyuan Xu

Affiliations

Soon will be listed here.

Abstract

Serum hepatitis B virus pregenomic RNA (HBV pgRNA) is a potential biomarker that is correlated with covalently closed circular DNA. The long-term dynamics of HBV pgRNA in patients with chronic hepatitis B need to be explored. One hundred naïve nucleos(t)ide analog-treated patients with chronic hepatitis B were enrolled to analyze the dynamics of HBV pgRNA over 9 years. The positive rates of HBV pgRNAs declined gradually and showed biphasic kinetics. Serum HBV pgRNA levels in patients treated with entecavir became negative later than those treated with adefovir or lamivudine. Patients who remain positive for HBV pgRNA after 9 years of treatment may have higher viral transcription efficiencies. The reverse transcription efficiency of hepatitis B e-antigen (HBeAg)-positive patients was higher than that of HBeAg-negative patients at baseline and showed no difference after 24-week nucleos(t)ide analog treatment. The trajectory of serum HBV pgRNA-negative transformation differs in patients with different characteristics. Long-term dynamic monitoring of serum HBV pgRNA levels has significance in hepatitis B treatment.

Citing Articles

Diagnostic Utility of Pre-Genomic Hepatitis B RNA in the Evaluation of HBV/HIV Coinfection.

Sherman K, Rouster S, Meeds H, Peters M, Blackard J, Horn P Pathog Immun. 2024; 9(2):43-57.

PMID: 39135958 PMC: 11318280. DOI: 10.20411/pai.v9i2.720.

Circulating HBV RNA and Hepatitis B Core-Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy.

Begre L, Boyd A, Plissonnier M, Testoni B, Salazar-Vizcaya L, Suter-Riniker F J Infect Dis. 2024; 230(4):e954-e963.

PMID: 38626170 PMC: 11481342. DOI: 10.1093/infdis/jiae189.

References

Van Damme E, Vanhove J, Severyn B, Verschueren L, Pauwels F . The Hepatitis B Virus Interactome: A Comprehensive Overview. Front Microbiol. 2021; 12:724877. PMC: 8482013. DOI: 10.3389/fmicb.2021.724877. View

Wang G, Guan J, Khan N, Li G, Shao J, Zhou Q . Potential capacity of interferon-α to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus. Gut Pathog. 2021; 13(1):22. PMC: 8040234. DOI: 10.1186/s13099-021-00421-9. View

Kramvis A, Kostaki E, Hatzakis A, Paraskevis D . Immunomodulatory Function of HBeAg Related to Short-Sighted Evolution, Transmissibility, and Clinical Manifestation of Hepatitis B Virus. Front Microbiol. 2018; 9:2521. PMC: 6207641. DOI: 10.3389/fmicb.2018.02521. View

Suslov A, Meier M, Ketterer S, Wang X, Wieland S, Heim M . Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity. J Hepatol. 2020; 74(4):794-800. DOI: 10.1016/j.jhep.2020.11.003. View

Liao H, Liu Y, Wang J, Cheng G, Xu D, Chen J . Letter to the Editor: The Differences Between the Reverse Transcriptional Efficiency of HBV Pregenomic RNA and Transcriptional Efficiency of HBV Covalently Closed Circular DNA. Hepatology. 2021; 74(3):1720-1721. DOI: 10.1002/hep.31786. View

Wu I, Liu W, Chiu Y, Chiu H, Cheng P, Chang T . Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss. Microorganisms. 2021; 9(6). PMC: 8229518. DOI: 10.3390/microorganisms9061146. View

Wang J, Shen T, Huang X, Kumar G, Chen X, Zeng Z . Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol. 2016; 65(4):700-710. DOI: 10.1016/j.jhep.2016.05.029. View

Wang G, Duan Z . Guidelines for Prevention and Treatment of Chronic Hepatitis B. J Clin Transl Hepatol. 2021; 9(5):769-791. PMC: 8516840. DOI: 10.14218/JCTH.2021.00209. View

Liu S, Zhou B, Valdes J, Sun J, Guo H . Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection. Hepatology. 2018; 69(4):1816-1827. PMC: 6438723. DOI: 10.1002/hep.30325. View

10.

Pan J, Xu J, Luo H, Tan N, Kang Q, Chen H . Factors and virological significance of hepatitis B virus pregenomic RNA status after 5 years of antiviral therapy. Int J Infect Dis. 2021; 105:418-423. DOI: 10.1016/j.ijid.2021.02.116. View

11.

Rattanachaisit P, Suksawatamnuay S, Sriphoosanaphan S, Thanapirom K, Thaimai P, Siripon N . Stability of hepatitis B virus pregenomic RNA in plasma specimens under various temperatures and storage conditions. PeerJ. 2021; 9:e11207. PMC: 8052958. DOI: 10.7717/peerj.11207. View

12.

Luo H, Tan N, Kang Q, Pan J, Chen H, Xi H . Hepatitis B virus pregenomic RNA status can reveal the long-term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues. J Viral Hepat. 2019; 27(3):323-328. DOI: 10.1111/jvh.13227. View

13.

Liu S, Liu Z, Li W, Zhou B, Liang X, Fan R . Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues. Aliment Pharmacol Ther. 2020; 52(4):692-700. DOI: 10.1111/apt.15890. View

14.

Mak L, Cloherty G, Wong D, Gersch J, Seto W, Fung J . HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy. Hepatology. 2020; 73(6):2167-2179. DOI: 10.1002/hep.31616. View

15.

Volz T, Lutgehetmann M, Wachtler P, Jacob A, Quaas A, Murray J . Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology. 2007; 133(3):843-52. DOI: 10.1053/j.gastro.2007.06.057. View